217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study - A. M. Joshua, H. Gurney, M. Retz, A. Tafreshi, P. C. C. Fong, N. D. Shore, E. Romano, M. Augustin, J. M. Piulats, W. R. Berry, M. P. Kolinsky, S. S. Sridhar, H. J. Conter, T. Todenhöfer, L. J. Appleman - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Annals of Oncology, (31), p. S1325, 2020

DOI: 10.1016/j.annonc.2020.10.437

Links

Tools

Export citation

Search in Google Scholar

217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study

Journal article published in 2020 by A. M. Joshua, H. Gurney, M. Retz, A. Tafreshi, P. C. C. Fong, N. D. Shore, E. Romano, M. Augustin, J. M. Piulats, W. R. Berry, M. P. Kolinsky, S. S. Sridhar, H. J. Conter, T. Todenhöfer, L. J. Appleman and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO